Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA. PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH). Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose. To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change of FDG uptake of heart
Timeframe: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
Change of FDG uptake of lungs
Timeframe: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
Change of the heart function
Timeframe: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
Change of the lung perfusion
Timeframe: before radiotherapy and up to 16 weeks after completion of radiotherapy